APA (7th ed.) Citation

Schwaab, J., Metzgeroth, G., Naumann, N., Jawhar, M., Fabarius, A., Hofmann, W., & Reiter, A. (2014). Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Annals of hematology, 94(2), . https://doi.org/10.1007/s00277-014-2221-y

Chicago Style (17th ed.) Citation

Schwaab, Juliana, Georgia Metzgeroth, Nicole Naumann, Mohamad Jawhar, Alice Fabarius, Wolf-Karsten Hofmann, and Andreas Reiter. "Limited Duration of Complete Remission on Ruxolitinib in Myeloid Neoplasms with PCM1-JAK2 and BCR-JAK2 Fusion Genes." Annals of Hematology 94, no. 2 (2014). https://doi.org/10.1007/s00277-014-2221-y.

MLA (9th ed.) Citation

Schwaab, Juliana, et al. "Limited Duration of Complete Remission on Ruxolitinib in Myeloid Neoplasms with PCM1-JAK2 and BCR-JAK2 Fusion Genes." Annals of Hematology, vol. 94, no. 2, 2014, https://doi.org/10.1007/s00277-014-2221-y.